Psilocybin

Nature Medicine Volume 32 Issue 7 自然医学 32卷 7期 https://www.nature.com/nm/volumes/32/issues/7 Editorial（社论） 1 Oncology must confront hidden side effects 肿瘤学必须正视隐匿不良反应 Nature Medicine volume 32（7）, page 2321 News（新闻） 2 Taming the inflamed heart 调控炎症性心脏病变 Charlotte Harrison Nature Medicine volume 32（7）, pages 2322-2323 News Feature（新闻专题） 3 When the real world becomes the trial 当现实世界成为临床试验场域 Marianne Guenot Nature Medicine volume 32（7）, pages 2324–2327 Correspondence（读者来信） 4 What Galen’s dissections reveal about tacit learning in modern medical education 盖伦解剖研究对现代医学教育中默会学习的启示 Andres PelavskiGabriele TorcolettiOrly Lewis Nature Medicine volume 32（7）, pages 2328–2329 5 What Utah’s clinical AI sandbox reveals about independent oversight 犹他州临床人工智能沙箱对独立监管机制的启示 Rahul GorijavoluNikhil JaiswalLeo Anthony Celi Nature Medicine volume 32（7）, pages 2330–2332 6 A case of artificial intelligence-enhanced diagnostics leading to heart transplantation 人工智能辅助诊断促成心脏移植一例 Heidi S. HartmanJoshua FinerPierre Elias Nature Medicine volume 32（7）, pages 2333–2334 7 Unintended consequences of legacy oversight in digital medicine 数字医学领域传统监管模式带来的非预期后果 Jochen K. LennerzDaniela AllendeAnne M. Stowman Nature Medicine volume 32（7）, pages 2335–2337 8 Incretin therapies, nutrition and food insecurity in the UK 英国肠促胰素治疗、营养状况与粮食不安全问题 Marie SpreckleyCara F. RuggieroAdrian Brown Nature Medicine volume 32（7）, pages 2338–2339 World View（全球观点） 9 Manageable toxicity is not a label — it is an oxymoron 可控制毒性并非标签，而是矛盾表述 From the patient’s perspective, toxicity is manageable only when it is met with empathy. 从患者视角而言，只有饱含人文关怀，不良反应才谈得上可控。 Laura Book Nature Medicine volume 32（7）, page 2340 10 Downplaying toxicities in cancer drug trials is not acceptable 肿瘤药物临床试验中淡化不良反应不可取 Bishal Gyawali Nature Medicine volume 32（7）, page 2341  Comment（述评） 11 Wearables as personal health custodians 可穿戴设备：个人健康守护者 Lei LuJosip Car Nature Medicine volume 32（7）, pages 2342–2345 12 Australia legislates against genetic discrimination in life insurance 澳大利亚立法禁止人寿保险领域的基因歧视 Jane Tiller Nature Medicine volume 32（7）, pages 2346–2348 13 A roadmap to competitive preclinical packages 具备竞争力的临床前研究方案构建路线图 Mustafa KhasrawMegan C. BenzJose R. Conejo-Garcia Nature Medicine volume 32（7）, pages 2349–2352 14 Brain Health for Economic Resilience: a data-driven framework for the brain-positive economic transition 保障大脑健康助力经济韧性：推动益脑经济转型的数据驱动框架 Harris A. EyreRym AyadiSimon Fischer-Baum Nature Medicine volume 32（7）, pages 2353–2355 News & Views（新闻与观点） 15 Long-term health risks of e-cigarettes after smoking cessation 戒烟后使用电子烟的长期健康风险 Mahdi SheikhPamela M. Ling Nature Medicine volume 32（7）, pages 2356–2357 16 CAR T cells take on precancers CAR-T细胞靶向癌前病变 Eric M. JurgensSham Mailankody Nature Medicine volume 32（7）, pages 2358–2359 17 Lassa fever countermeasures gather pace 拉沙热防控举措加速推进 Daniel Jenkin Nature Medicine volume 32（7）, pages 2360–2361 18 Shifting the goalposts in obesity drug development 肥胖药物研发目标的重新界定 W. Timothy Garvey Nature Medicine volume 32（7）, pages  pages 2362–2363 Research Briefings（研究简报） 19 General-purpose chatbots outperform clinical AI tools on physicians’ real-world questions 通用对话机器人在医师现实临床问题上表现优于专用临床人工智能工具 Nature Medicine volume 32（7）, pages 2364–2365 20 An AI framework for multi-disease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Nature Medicine volume 32（7）, pages 2366–2367 Perspectives（前瞻观点） 21 Immune aging biomarkers for clinical trials 适用于临床试验的免疫衰老生物标志物 Andrea CiprianoJamie JusticeChiara M. S. Herzog Nature Medicine volume 32（7）, pages 2368–2382 Review Articles（综述） 22 Biological aging clocks in health and disease 健康与疾病状态下的生物学衰老时钟 Tony Wyss-CorayEric J. Topol Nature Medicine volume 32（7）, pages 2383–2394 Matters Arising（学术争鸣） 23 Limited evidence of AI superiority in seasonal influenza vaccine strain selection 尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势 Simon P. J. de JongColin A. Russell Nature Medicine volume 32（7）, pages 2395–2397 24 Reply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selection 对《尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势》一文的回应 Wenxian ShiJeremy WohlwendRegina Barzilay Nature Medicine volume 32（7）, pages 2398–2400 Brief Communications（简讯） 25 Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba 2024年古巴奥罗普切热暴发的时空传播特征 Rosario GravierMelissa M. PerezMaria G. Guzman Nature Medicine volume 32（7）, pages 2401–2404 26 General-purpose large language models outperform specialized clinical AI tools on medical benchmarks 通用大语言模型在医学基准测试中优于专用临床人工智能工具 Krithik VishwanathAnton AlyakinEric Karl Oermann Nature Medicine volume 32（7）, pages 2405–2409 Articles（论著） 27 Electronic cigarette use after smoking cessation and lung cancer risk 戒烟后使用电子烟与肺癌风险 Yeon Wook KimEung Joo ParkChoon-Taek Lee Nature Medicine volume 32（7）, pages 2410–2419 28 Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial Ciltacabtagene autoleucel治疗高危冒烟型（无症状）多发性骨髓瘤：CAR-PRISMⅡ期临床试验 Omar NadeemDavid M. Cordas dos SantosIrene M. Ghobrial Nature Medicine volume 32（7）, pages 2420–2429 29 Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial Cibisatamab联合FAP-4-1BBL治疗微卫星稳定型结直肠癌：Ⅰb期临床试验 Ignacio MeleroTamara TanosVictor Moreno Nature Medicine volume 32（7）, pages 2430–2439 30 Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, pages 2440–2448 31 Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial 抗LAG-3单抗联合或不联合抗PD-1单抗治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Michael LimXiaobu YeStuart A. Grossman Nature Medicine volume 32（7）, pages 2449–2460 32 Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial 立体定向体部放疗联合度伐利尤单抗与奥来鲁单抗新辅助治疗ER阳性HER2阴性乳腺癌：随机Ⅱ期临床试验 Alex De CaluwéIsabelle DesmoulinsLaurence Buisseret Nature Medicine volume 32（7）, pages 2461–2472 33 Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial ctDNA阳性结直肠癌术后辅助化疗：随机Ⅲ期临床试验 Hideaki BandoJun WatanabeTakeshi Kato Nature Medicine volume 32（7）, pages 2473–2480 34 Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie GomezRachel A. DiCioccioEugene I. Hwang Nature Medicine volume 32（7）, pages 2481–2493 35 AI framework for multidisease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Xiayin ZhangQinyi LiHonghua Yu Nature Medicine volume 32（7）, pages 2494–2503 36 Long-term independent use of an intracortical brain–computer interface for speech and cursor control 皮层内脑机接口用于语音与光标控制的长期独立应用研究 Nicholas S. CardTyler Singer-ClarkDavid M. Brandman Nature Medicine volume 32（7）, pages 2504–2510 37 Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial 含佐剂灭活狂犬病毒载体拉沙病毒疫苗在健康成人中的Ⅰ期临床试验 Justin R. OrtizDrishya KurupMatthias J. Schnell Nature Medicine volume 32（7）, pages 2511–2521 38 Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial 法匹拉韦治疗拉沙热：开放标签随机对照Ⅱ期临床试验 Cyril EramehKevin OkwaraekeMirjam Groger Nature Medicine volume 32（7）, pages 2522–2532 39 Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial 双特异性广谱中和抗体10E8.4/iMab在HIV-1感染者与健康人群中的部分随机Ⅰ期临床试验 Deborah A. TheodoreBryan T. MayerMagdalena E. Sobieszczyk Nature Medicine volume 32（7）, pages 2533–2545 40 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial 15菌株活体生物制剂与同源供体粪菌移植治疗复发性艰难梭菌感染：随机Ⅰb期临床试验 Lukas BethlehemLorenza BartuAri Grinspan Nature Medicine volume 32（7）, pages 2546–2555 41 Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection 固有免疫应答水平可预测人工流感感染后细胞免疫增强与临床发病情况 Loukas PapargyrisJiayun XuChristopher Chiu Nature Medicine volume 32（7）, pages 2556–2569 42 Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial 多巴胺激动剂普拉克索治疗快感缺失型抑郁症的疗效与靶点作用验证：随机安慰剂对照试验 Filip VentorpMarie AspDaniel Lindqvist Nature Medicine volume 32（7）, pages 2570–2578 43 Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial 脊髓电刺激改善慢性卒中后偏瘫患者上肢运动功能：可行性临床试验 Roberto M. de FreitasShovan BhatiaMarco Capogrosso Nature Medicine volume 32（7）, pages 2579–2590 44 A neuroprosthesis for restoring hand movement and sensation in a person with complete tetraplegia 神经假体用于重建完全四肢瘫痪患者手部运动与感觉功能 Santosh ChandrasekaranSarah K. WandeltChad E. Bouton Nature Medicine volume 32（7）, pages  pages2591–2601 45 Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial 双靶点基因疗法治疗帕金森病：多中心Ⅰ期临床试验 Mengyue NiuJifeng GuoJun Liu Nature Medicine volume 32（7）, pages 2602–2609 46 Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial 阿巴西普对比羟氯喹预防复发性风湿症进展为类风湿关节炎：随机开放标签试验 Raimon SanmartiCarolina Pérez-GarcíaIsabel Haro Nature Medicine volume 32（7）, pages 2610–2618 47 Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial 寡核苷酸-siRNA偶联药物治疗SOD1相关肌萎缩侧索硬化：Ⅰ期临床试验 Weiqi ChenLingling JiangYilong Wang Nature Medicine volume 32（7）, pages 2619–2628 48 Multinational validation of the PREVENT and SCORE2心血管风险方程 across 6.4 million individuals 基于640万人群的多国验证：PREVENT与SCORE2心血管风险预测方程 Brendon L. NeuenRupert W. MajorVilmantas Giedraitis Nature Medicine volume 32（7）, pages 2629–2638 49 Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial Cliramitug清除心脏转甲状腺素蛋白淀粉样物质：NI006-101试验长期随访结果 Peter C. KahrFabian aus dem SiepenPeter van der Meer Nature Medicine volume 32（7）, pages 2639–2646 50 Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial 小剂量地高辛治疗射血分数降低或轻度降低心力衰竭：随机对照试验 D. J. van VeldhuisenM. RienstraP. van der Meer Nature Medicine volume 32（7）, pages 2647–2653 51 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 微小RNA抑制剂CDR132L治疗心肌梗死后左室射血分数降低患者：随机Ⅱ期临床试验 Johann BauersachsScott D. SolomonThomas Thum Nature Medicine volume 32（7）, pages 2654–2661 52 Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial 司美格鲁肽对比安慰剂治疗减重手术术后减重不佳人群：双盲随机安慰剂对照试验 Chloe StanleyRitwika MallikJanine Makaronidis Nature Medicine volume 32（7）, pages 2662–2672 53 Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Apitegromab用于替尔泊肽减重过程中维持瘦体重：随机双盲安慰剂对照Ⅱ期临床试验 Richard E. PratleyDouglas Scott DenhamJing L. Marantz Nature Medicine volume 32（7）, pages 2673–2678 54 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Orforglipron用于维持减重效果：双盲随机Ⅲb期ATTAIN-MAINTAIN试验 Louis J. AronneDeborah B. HornNeena Xavier Nature Medicine volume 32（7）, pages 2679–2687 Amendments & Corrections（勘误与更正） 55 Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 作者更正：基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, page 2688 56 Author Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial 作者更正：数字虚拟化身疗法治疗精神病幻听症状：Ⅱ/Ⅲ期AVATAR2临床试验 Philippa A. GaretyClementine J. EdwardsThomas Ward Nature Medicine volume 32（7）, page 2689 57 Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study 作者更正：1990–2023年204个国家苯丙胺、大麻、可卡因与阿片类物质使用的全球疾病负担研究 Jiseung KangHyeon Jin KimDong Keon Yon Nature Medicine volume 32（7）, page 2690 58 Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial 撤稿声明：时辰免疫化疗治疗非小细胞肺癌：随机Ⅲ期临床试验 Zhe HuangLiang ZengYongchang Zhang Nature Medicine volume 32（7）, page 2691 Nature Medicine Volume 32 Issue 8 自然医学 32卷 8期 https://www.nature.com/nm/volumes/32/issues/8 Editorial（社论） 1 Anti‑aging interventions need less hype and more clinical evidence 抗衰老干预：少一些炒作，多一些临床证据 Editorial Nature Medicine volume 32（8）, page 2693 News（新闻） 2 A turning point for gene editing in severe blood disorders 基因编辑治疗重症血液疾病迎来转折点 Carrie Arnold Nature Medicine volume 32（8）, pages 2694-2696 News Feature（新闻特写） 3 Sleep as therapy 睡眠疗法 Carrie Arnold Nature Medicine volume 32（8）, pages 2697–2700 Correspondence（通信） 4 Genetic–exposome interactions and aging clocks in dementia: the ReDLat2 initiative 遗传‑暴露组相互作用与痴呆衰老时钟：ReDLat2研究计划 Agustin IbáñezJennifer S. YokoyamaBruce L. Miller Nature Medicine volume 32（8）, pages 2701–2703 5 Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures 无疫苗与治疗药物情况下的本迪布焦埃博拉疫情：公共卫生基础措施比边境封锁更为重要 Ngashi NgongoMosoka Papa FallahJean Kaseya Nature Medicine volume 32（8）, pages 2704–2705 6 Fertilizer scarcity as a failure of global health governance 肥料短缺：全球卫生治理的一项失败 Alaha NasariAmina NasariJessica Fanzo Nature Medicine volume 32（8）, pages 2706–2707 7 Mapping the human chemical exposome for public health 面向公共卫生的人类化学暴露组图谱绘制 Arthur DavidSarah LennonMichel Samson Nature Medicine volume 32（8）, pages 2708–2710 World View（全球视野） 8 When caution becomes harm 当谨慎变为伤害 Simone N. Vigod Nature Medicine volume 32（8）, page 2711 Comment（述评） 9 Enabling secure discovery in trusted research environments with improved tooling 依托优化工具在可信研究环境中实现安全数据挖掘 Vincent J. StraubMelinda C. Mills Nature Medicine volume 32（8）, pages 2712–2715 10 Reinventing biotech systems for patient impact 重塑生物技术体系，惠及患者 Kushal T. KadakiaYashodhara DashAnaeze C. Offodile II Nature Medicine volume 32（8）, pages 2716–2719 11 Why large‑scale randomized trials of live‑attenuated shingles vaccination for dementia prevention are urgently needed 亟需开展减毒活带状疱疹疫苗预防痴呆的大规模随机对照试验 Pascal Geldsetzer Nature Medicine volume 32（8）, pages 2720–2723 12 Inspiring, shaping and sustaining an African research & development agenda 推动、构建并维系非洲研发议程 Mosoka P. FallahMisaki WayengeraJean Kaseya Nature Medicine volume 32（8）, pages 2724–2726 13 Data rights are the missing pillar for modernizing consent in medicine 数据权利：医学知情同意现代化的缺失支柱 Nada S. Salem Nature Medicine volume 32（8）, pages 2727–2728 Q&A（问答） 14 Reinventing health communication for the digital era 数字时代下重塑健康传播 Natalie Healey Collection: Nature Medicine Commission on Quality Health Information for All Nature Medicine volume 32（8）, pages 2729–2731 News & Views（新闻与观点） 15 Adaptive brain stimulation 2.0 for Parkinsonian gait 用于帕金森病步态障碍的第二代自适应脑刺激 Arjun BalachandarAlfonso Fasano Nature Medicine volume 32（8）, pages 2732–2734  16 A second chance for gene therapy to restore natural hearing 基因治疗重获契机，助力恢复天然听力 Nicola Strenzke Nature Medicine volume 32（8）, pages 2735–2737 17 From RAS inhibitor resistance to rational combination strategies 从RAS抑制剂耐药到合理联合治疗策略 Paula LynchTeresa MacarullaGrainne M. O’Kane Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2738–2740  18 Deciphering the role of histidine in cancer 解析组氨酸在肿瘤中的作用 Feyza CansizAmanda N. PopeAlpaslan Tasdogan Nature Medicine volume 32（8）, pages 2741–2742 Research Briefings（研究简报） 19 Learning from routine health system data builds better neuroimaging AI models 基于常规卫生系统数据训练构建更优神经影像人工智能模型 Research Briefing Nature Medicine volume 32（8）, pages 2743–2744 20 Early detection of Alzheimer’s disease with circular RNA from blood 基于血液环状RNA实现阿尔茨海默病早期检测 Nature Medicine volume 32（8）, pages 2745–2746 21 Non‑invasive tests for the evaluation of liver fibrosis in MASLD 代谢相关脂肪性肝病肝纤维化的无创评估检测 Nature Medicine volume 32（8）, pages 2747–2748 22 Multi‑omics maps human–pig interactions in extracorporeal liver cross‑circulation 多组学解析体外肝交叉循环中人‑猪相互作用 Nature Medicine volume 32（8）, pages 2749–2750 23 Biological aging might help to explain the rising risk of early‑onset cancer 生物衰老或可解释早发性肿瘤风险升高现象 Nature Medicine volume 32（8）, pages 2751–2752 24 Delivering the benefits of genomic data reanalysis for diagnosis equitably and at scale 公平、规模化发挥基因组数据再分析的诊断价值 Nature Medicine volume 32（8）, pages 2753–2754 25 Why high scores do not mean application readiness for health AI 为何高分不等于健康人工智能具备实际应用就绪度 Nature Medicine volume 32（8）, pages 2755–2756 Perspectives（观点） 26 Type 2 diabetes prevention across the life course 全生命周期的2型糖尿病预防 Yiying WangJennifer L. SargentAndreas L. Birkenfeld Nature Medicine volume 32（8）, pages 2757–2773 27 The next generation of antibody–drug conjugates 新一代抗体‑药物偶联物 F. MoseleA. PeltierF. André Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2774–2785 Brief Communications（简讯） 28 Clinical profile and genomic characterization of the 2026 Bundibugyo virus index case in Uganda 乌干达2026年本迪布焦病毒首发病例的临床特征与基因组分析 Andrew NsawotebbaIsaac SsewanyanaDiana Atwine Nature Medicine volume 32（8）, pages 2786–2789 Articles（论著） 29 Immersive virtual reality with synchronous neurostimulation for upper‑limb recovery after stroke: a randomized feasibility trial 沉浸式虚拟现实联合同步神经刺激用于脑卒中后上肢功能恢复：一项随机可行性试验 Giuseppe Valerio AurucciOlivera DjordjevicStanisa Raspopovic Nature Medicine volume 32（8）, pages 2790–2802 30 Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial 自适应深部脑刺激用于帕金森病动态步态调控：一项随机可行性试验 Kenneth H. LouieJannine P. BalakidDoris D. Wang Nature Medicine volume 32（8）, pages 2803–2814 31 Activity‑dependent adaptive deep brain stimulation improves gait in Parkinson’s disease 活动依赖性自适应深部脑刺激改善帕金森病患者步态 Stefano ScafaValeria de SetaEduardo M. Moraud Nature Medicine volume 32（8）, pages 2815–2830 32 Health system learning enables generalist neuroimaging models 基于卫生系统数据学习构建通用型神经影像模型 Akhil KondepudiAkshay RaoTodd Hollon Nature Medicine volume 32（8）, pages 2831–2837 33 Individualized antisense oligonucleotides for SCN2A‑related developmental epileptic encephalopathy 针对SCN2A相关发育性癫痫性脑病的个体化反义寡核苷酸治疗 Olivia Kim‑McManusLaurence MignonElizabeth Berry‑Kravis Nature Medicine volume 32（8）, pages 2838–2845 34 Re‑administration of AAV‑mediated gene therapy for OTOF‑related deafness: a single‑arm trial OTOF相关耳聋腺相关病毒介导基因治疗的再次给药：一项单臂临床试验 Xintai FanLonglong ZhangYilai Shu Nature Medicine volume 32（8）, pages 2846–2856 35 Blood‑based circular RNAs for early diagnosis of Alzheimer’s disease 基于血液环状RNA的阿尔茨海默病早期诊断 Bridget PhillipsJessie SanfordCarlos Cruchaga Nature Medicine volume 32（8）, pages 2857–2864 36 Acquired resistance to the RAS(ON) multi‑selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer RAS(ON)高选择性抑制剂daraxonrasib获得性耐药指导胰腺癌合理联合治疗策略 Ida AronchikSumit KarMallika Singh Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2865–2877 37 MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, pages 2878–2887 38 Savolitinib in MET‑amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 赛沃替尼治疗MET扩增胃癌或胃食管结合部腺癌：Ⅱ期临床试验 Zhi PengTianshu LiuZhongxian Zheng Nature Medicine volume 32（8）, pages 2888–2897  39 SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, pages 2898–2908 40 FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial FcRH5×CD3双特异性抗体ce vostamab治疗复发难治多发性骨髓瘤：Ⅰ期临床试验 Adam D. CohenJoshua RichterAmrita Krishnan Nature Medicine volume 32（8）, pages 2909–2917 41 Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling 基于血浆谱分析筛选肿瘤免疫治疗疗效的代谢决定因素 Déborah SuissaMarine FidelleLaurence Zitvogel Nature Medicine volume 32（8）, pages 2918–2932 42 Polypill for heart failure with reduced ejection fraction: the POLY‑HF randomized trial 射血分数降低心力衰竭复方制剂：POLY‑HF随机临床试验 Ambarish PandeyNeil KeshvaniThomas J. Wang Nature Medicine volume 32（8）, pages 2933–2940 43 Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, pages 2941–2947 44 Survodutide in adults with obesity and metabolic dysfunction‑associated steatotic liver disease: SYNCHRONIZE‑MASLD, a randomized, double‑blind, placebo‑controlled phase 3 trial Survodutide治疗合并代谢相关脂肪性肝病的肥胖成人：SYNCHRONIZE‑MASLD随机双盲安慰剂对照Ⅲ期临床试验 Lee M. KaplanElena StartsevaPaul Hellstern Nature Medicine volume 32（8）, pages 2948–2958 45 Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study 代谢相关脂肪性肝炎及肝纤维化影像与血清诊断生物标志物的前瞻性验证：LITMUS影像研究 Michael PavlidesYasaman ValiQuentin M. Anstee Nature Medicine volume 32（8）, pages 2959–2969 46 Longitudinal multiomics profiling of extracorporeal cross‑circulation with pig liver xenografts in human decedents 人逝者猪肝异种移植体外交叉循环的纵向多组学分析 Qian GuoChan WangBrendan J. Keating Nature Medicine volume 32（8）, pages 2970–2982 47 Biological aging and generational shifts in early‑onset cancer risk 生物衰老与早发性肿瘤风险的代际变迁 Ruiyi TianXiaoyu ZongYin Cao Nature Medicine volume 32（8）, pages 2983–2990 48 Automated reanalysis of genomic data for rare disease diagnostics at scale 面向大规模罕见病诊断的基因组数据自动化再分析 Matthew J. WellandK. D. AhlquistZornitza Stark Nature Medicine volume 32（8）, pages 2991–2999 49 Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people 可解释人工智能皮肤病诊断对临床医师与普通人群的差异化影响 Xuhai ‘Orson’ XuHaoyu HuMarzyeh Ghassemi Nature Medicine volume 32（8）, pages 3000–3009 50 Generalizable AI predicts immunotherapy outcomes across cancers and treatments 泛化人工智能跨肿瘤类型与治疗方案预测免疫治疗疗效 Wanxiang ShenIntae MoonMarinka Zitnik Nature Medicine volume 32（8）, pages 3010–3022 51 Evaluating the robustness and readiness of large frontier models in health AI applications 健康人工智能应用中大前沿模型的稳健性与就绪度评估 Yu GuJingjing FuPaul Vozila Nature Medicine volume 32（8）, pages 3023–3031 52 Generative AI‑enabled clinical decision support system in primary care: a pragmatic, cluster‑randomized trial 基层医疗机构生成式人工智能临床决策支持系统：一项实用整群随机试验 Ambrose AgweyuPaul MwanikiBilal A. Mateen Nature Medicine volume 32（8）, pages 3032–3039 53 Integrated care pathway in individuals with Long COVID: STIMULATE‑ICP, a cluster‑randomized, phase 3 trial 长新冠患者综合护理路径：STIMULATE‑ICP整群随机Ⅲ期临床试验 Amitava BanerjeeGordon PrescottYi Mu Nature Medicine volume 32（8）, pages 3040–3047 54 Maternal 6‑valent group B Streptococcus vaccine in non‑pregnant and pregnant females: a randomized phase 1/2 trial B族链球菌六价母体疫苗在非妊娠及妊娠女性中的随机Ⅰ/Ⅱ期临床试验 Shabir A. MadhiHasra SnaggsAlejandra Gurtman Nature Medicine volume 32（8）, pages 3048–3059 55 The genetic architecture of fibromyalgia across 2.5 million individuals 基于250万人群的纤维肌痛遗传结构研究 Isabel KerrebijnGyda BjornsdottirMichael Wainberg Nature Medicine volume 32（8）, pages 3060–3070 56 Povorcitinib for hidradenitis suppurativa: the randomized, double‑blind, placebo‑controlled STOP‑HS1 and STOP‑HS2 phase 3 trials Povorcitinib治疗化脓性汗腺炎：随机双盲安慰剂对照STOP‑HS1、STOP‑HS2两项Ⅲ期临床试验 Martina L. PorterAntonio MartorellChristos C. Zouboulis Nature Medicine volume 32（8）, pages 3071–3081 Analysis（分析） 57 A meta‑analysis of the long‑term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials 纳入51项随机试验的降压治疗对主要心血管病风险长期影响的荟萃分析 Qianqian YangZeinab BidelKazem Rahimi Nature Medicine volume 32（8）, pages 3082–3092 Amendments & Corrections（修订与勘误） 58 Author Correction: SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 作者勘误：靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, page 3093 59 Author Correction: MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 作者勘误：靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, page 3094 60 Publisher Correction: Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 出版方勘误：口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, page 3095 Nature Medicine Volume 32 Issue 9 自然医学 32卷 9期 https://www.nature.com/nm/volumes/32/issues/9 Editorial（社论） 1 To bridge the evidence gap in women’s health, look at the real world 弥合女性健康领域证据缺口：着眼真实世界 Nature Medicine volume 32（9）, page3097 News（新闻） 2 AI decision support is scaling-up fast — can the evidence keep up? AI决策支持系统快速普及——证据能否跟上发展？ Paul Webster Nature Medicine volume 32（9）, pages 3098–3099 News Feature（新闻特写） 3 Can traditional medicines go mainstream? 传统药物能否走向主流？ Ben Deighton Nature Medicine volume 32（9）, pagespages 3100–3103 Correspondence（通信） 4 Global access to different classes of diabetes medicines: a framework for targeted policy actions 不同类别糖尿病药物的全球可及性：一项针对性政策行动框架 Felix Teufel, Nomathemba Chandiwana, Till Bärnighausen Nature Medicine volume 32（9）, pages 3104–3106 5 A new additive in the opioid supply is causing disastrous complications 阿片类药物供应链中的新型添加物引发严重并发症 Cara Borelli Nature Medicine volume 32（9）, page 3107 6 Reconstructing disease burden data in armed conflict 武装冲突地区疾病负担数据的重建 Hussein ALMasri, Zining Luo, Huda Lahham Nature Medicine volume 32（9）, pages 3108–3109 7 Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty 监管碎片化：区域疫苗自主的隐性障碍 Mnotho Ngcobo Nature Medicine volume 32（9）, pages 3110–3111 8 Food is medicine: an opportunity to transform nutrition care in oncology 食物即药物：肿瘤营养诊疗变革的机遇 Fang Fang Zhang Nature Medicine volume 32（9）, pages 3112–3113 World View（全球观点） 9 Obesity medicines as disruptive innovation 作为颠覆性创新的肥胖治疗药物 Naveed Sattar Nature Medicine volume 32（9）, page 3114  Comment（述评） 10 Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria 2024版McDonald诊断标准出台后多发性硬化面临的挑战与未来方向 Jiwon Oh, Frederik Barkhof, Peter A. Calabresi Nature Medicine volume 32（9）, pages 3115–3119 11 Studying vanishing dietary diversity before it is lost: the World Diet Initiative 在饮食多样性消失前开展研究：世界饮食计划 Quirijn de Mast, Carly V. Brown, Mihai G. Netea Nature Medicine volume 32（9）, pages 3120–3123 12 Governing the social production of care: the hidden foundation of health systems 照护的社会供给治理：卫生体系的隐性基石 Jo-An Occhipinti, Ante Prodan, J. Jaime Miranda Nature Medicine volume 32（9）, pages 3124–3127 13 Toward a test of medical AI superintelligence 迈向医学人工智能超级智能的检验 Ethan Goh, David Wu, Jonathan H. Chen Nature Medicine volume 32（9）, pages 3128–3130 14 Rethinking the global health system for a new international order 面向国际新秩序重新思考全球卫生体系 Kumanan Rasanathan, Keith Cloete, John-Arne Røttingen Nature Medicine volume 32（9）, pages 3131–3135 News & Views（新闻与观点） 15 A multimodal murmuration for immunotherapy 免疫治疗的多模态协同效应 Raquel Perez-Lopez, Mireia Crispin-Ortuzar Nature Medicine volume 32（9）, pages 3136–3137 16 Beyond the breakthrough for RAS-driven cancers RAS驱动肿瘤：突破之外的探索 Rich C. King, Erica S. Tsang, Jennifer J. Knox Nature Medicine volume 32（9）, pages 3138–3139 17 Waking from the nightmare of PTSD 从创伤后应激障碍的梦魇中苏醒 Murray B. Stein Nature Medicine volume 32（9）, pages 3140–3141 18 The trials of translating psilocybin treatment from research to practice 裸盖菇素治疗从研究走向临床应用的挑战 Liliana Galindo, Anya Ragnhildstveit, Benjamin J. G. Illingworth Nature Medicine volume 32（9）, pages 3142–3143 19 Putting epigenetic aging clocks on trial 表观遗传衰老时钟的临床验证 Steve Horvath Nature Medicine volume 32（9）, pages 3144–3145 Research Briefings（研究简报） 20 County surveillance failed to detect that measles transmission reached epidemic threshold in schools 县级监测未能发现麻疹在学校传播已达流行阈值 Nature Medicine volume 32（9）, pages 3146–3147 21 The px1 locus is linked to declining susceptibility to malaria drugs in Uganda 乌干达px1基因座与抗疟药物敏感性下降相关 Nature Medicine volume 32（9）, pages 3148–3149 22 Isthmin 2 could determine the early origins of preeclampsia and fetal growth restriction Isthmin 2可提示子痫前期与胎儿生长受限的早期起源 Nature Medicine volume 32（9）, pages 3150–3151 23 Scaling rapid whole-genome sequencing for critical pediatric care in the Middle East 中东地区危重患儿快速全基因组测序的规模化应用 Nature Medicine volume 32（9）, pages 3152–3153 Perspectives（观点） 24 How to build an AI-driven digital organism 如何构建人工智能驱动的数字有机体 Le Song, Eran Segal, Eric Xing Nature Medicine volume 32（9）, pages 3154–3163 Review Articles（综述） 25 Induced pluripotent stem cells from discovery to translation 诱导多能干细胞：从发现到临床转化 Jaecheol Lee, Todd Herron, Joseph C. Wu Nature Medicine volume 32（9）, pages 3164–3180 Articles（论著） 26 County, district and community-level measles transmission in the United States in 2013−2025 2013–2025年美国县、辖区及社区层面的麻疹传播 Siyu Chen, Ana I. Bento Nature Medicine volume 32（9）, pages 3181–3191 27 Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda 乌干达恶性疟原虫PX1多态性（与抗疟药敏感性下降相关）的出现与传播 Karamoko Niaré, Bersabeh Tafesse, Melissa D. Conrad Nature Medicine volume 32（9）, pages 3192–3202 28 End-to-end multimodal pathology foundation model with clinical dialogue 具备临床对话能力的端到端多模态病理基础大模型 Eugene Vorontsov, George Shaikovski, Siqi Liu Nature Medicine volume 32（9）, pages 3203–3213 29 AI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trial 基于AI的遗传性视网膜疾病临床决策支持系统：一项多中心随机试验 Huixun Jia, Bo Qian, Xiaodong Sun Nature Medicine volume 32（9）, pages 3214–3223 30 Clinical decision support in hematological malignancies using a case-grounded AI agent 基于案例AI智能体用于血液恶性肿瘤的临床决策支持 Julian Zoller, Michael Kalz, Mirco J. Friedrich Nature Medicine volume 32（9）, pages 3224–3234 31 Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC 可解释AI决策支持工具在非小细胞肺癌中的临床可用性及多模态模型评估 Arsela Prelaj, Vanja Miskovic, Giovanni Scoazec Nature Medicine volume 32（9）, pages 3235–3247 32 An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial 携带Gq/11抑制剂载荷的抗PMEL抗体药物偶联物治疗GNAQ/GNA11突变黑色素瘤：Ⅰ期临床试验 Matteo S. Carlino, Ellen Kapiteijn, Emiliano Calvo Nature Medicine volume 32（9）, pages 3248–3258 33 Englumafusp alfa plus glofitamab in Bcell non-Hodgkin lymphoma: a phase 1 trial Englumafusp alfa联合格罗非单抗治疗B细胞非霍奇金淋巴瘤：Ⅰ期临床试验 Martin Hutchings, Michael Dickinson, Franck Morschhauser Nature Medicine volume 32（9）, pages 3259–3267 34 Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial 颅内输注靶向B7-H3的CAR-T细胞治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Yang Zhang, Xiaohan Chi, Gangxiong Huang Nature Medicine volume 32（9）, pages 3268–3275 35 Decade-long persistence of CD19 CAR T cells in B cell lymphomas CD19 CAR-T细胞在B细胞淋巴瘤体内可长达十年持续存在 Luca Paruzzo, Emeline R. Chong, Marco Ruella Nature Medicine volume 32（9）, pages 3276–3287 36 First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial PD-1/VEGF双特异性抗体联合化疗一线治疗三阴性乳腺癌：Ⅱ期临床试验 Xiying Shao, Can Tian, Quchang Ouyang Nature Medicine volume 32（9）, pages 3288–3293 Collection: Cancer at Nature Portfolio 合集：Nature系列肿瘤专题 37 KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial KRAS-G12D抑制剂HRS-4642联合化疗治疗晚期KRASG12D突变胰腺癌：Ⅰb/Ⅱ期临床试验 Jiujie Cui, Kuirong Jiang, Liwei Wang Nature Medicine volume 32（9）, pages 3294–3301 38 Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial 口服KRAS G12D抑制剂GFH375用于经治晚期KRAS G12D突变实体瘤：Ⅰ期临床试验 Xinghao Ai, Zhengbo Song, Shun Lu Nature Medicine volume 32（9）, pages 3302–3312 39 Global breast cancer survival estimates in 2017–2021 to advance the WHO Global Breast Cancer Initiative 2017–2021全球乳腺癌生存率估算，助力WHO全球乳腺癌防治计划 Fabio Girardi, Mary Nyangasi, André M. Ilbawi Nature Medicine volume 32（9）, pages 3313–3321 40 Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Mitiperstat抑制髓过氧化物酶治疗射血分数保留或轻度降低心力衰竭：一项随机Ⅱb期试验 Lars H. Lund, Carolyn S. P. Lam, Sanjiv J. Shah Nature Medicine volume 32（9）, pages 3322–3330 41 Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial 心肌内注射同种异体人诱导多能干细胞来源心肌细胞治疗晚期缺血性心力衰竭：一项早期随机试验 He Zhang, Phlippe Menasche, Dongjin Wang Nature Medicine volume 32（9）, pages 3331–3338 42 Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial 靶向RAGE的吸入型siRNA治疗肺部炎症：首次人体随机试验 Mark O’Carroll, David Kasahara, Nadwipa Yuangtrakul Nature Medicine volume 32（9）, pages 3339–3350 43 Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction Isthmin-2可在孕早期预测子痫前期与胎儿生长受限 Ruoyu Miao, Sungsam Gong, Anna Sandström Nature Medicine volume 32（9）, pages 3351–3358 44 Citywide implementation of a rapid whole-genome sequencing program for critically ill pediatric patients 面向危重患儿的全市快速全基因组测序项目落地实施 Fatma Rabea, Ibtesam Aljasmi, Ahmad Abou Tayoun Nature Medicine volume 32（9）, pages 3359–3371 45 A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial CD3×CD19双特异性抗体治疗系统性红斑狼疮：Ⅰ期临床试验 Jason Xu, Chunli Mei, Qiubai Li Nature Medicine volume 32（9）, pages 3372–3384 46 Antifungal therapy improves microbiome dynamics in inflammatory bowel disease 抗真菌治疗可改善炎症性肠病的微生物组动态特征 Xiangyu Pan, Aidan Conroy, Iliyan D. Iliev Nature Medicine volume 32（9）, pages 3385–3395 47 Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial 屈大麻酚治疗创伤后应激障碍相关噩梦：一项随机对照试验 Stefan Roepke, Nikola Schoofs, Stefanie Koglin Nature Medicine volume 32（9）, pages 3396–3405 48 Global economic burden of depression in 154 countries from 2025 to 2050 2025–2050年154个国家抑郁症的全球经济负担 Zhong Cao, Yuheng Luo, Simiao Chen Nature Medicine volume 32（9）, pages 3406–3416 49 Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS 纵向血浆蛋白质组学可预测肌萎缩侧索硬化表型转化至临床发病 Ximing Ran, Joanne Wuu, Michael Benatar Nature Medicine volume 32（9）, pages 3417–3429 50 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial 公立医疗体系中裸盖菇素辅助治疗难治性重度抑郁症：随机对照试验 James J. Rucker, Tim Mantingh, Allan H. Young Nature Medicine volume 32（9）, pages 3430–3437 51 An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up iPSC来源神经前体细胞治疗亚急性脊髓损伤：带长期随访的Ⅰ期临床试验 Keiko Sugai, Osahiko Tsuji, Hideyuki Okano Nature Medicine volume 32（9）, pages 3438–3448 52 Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial 人胚胎干细胞来源多巴胺能细胞治疗帕金森病：Ⅰ/Ⅱ期开放标签试验 G. Paul, H. Bjartmarz, R. A. Barker Nature Medicine volume 32（9）, pages 3449–3457 53 Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial 短效抗PD-L1抗体免疫治疗阿尔茨海默病：Ⅰb期随机双盲试验 Tommaso Croese, Catherine J. Mummery, Michal Schwartz Nature Medicine volume 32（9）, pages 3458–3465 54 Histological aging signatures for monitoring tissue-specific aging and disease 用于监测组织特异性衰老与疾病的组织学衰老特征 Ernesto Abila, Iva Buljan, André F. Rendeiro Nature Medicine volume 32（9）, pages 3466–3476 Analysis（分析） 55 Responsiveness of epigenetic aging biomarkers to longevity interventions in humans 人类表观遗传衰老生物标志物对长寿干预措施的应答性 Raghav Sehgal, Daniel Borrus, Albert Higgins-Chen Nature Medicine volume 32（9）, pages 3477–3490 Amendments & Corrections（修订与勘误） 56 Author Correction: Evolution of claudin18.2 therapies in gastroesophageal cancers 作者勘误：Claudin18.2靶向疗法在胃食管肿瘤中的研究进展 Samuel J. Klempner, Raghav Sundar Nature Medicine volume 32（9）, page 3491  57 Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms 作者勘误：组织细胞肿瘤中CSF1R及其他受体酪氨酸激酶的激活突变 Benjamin H. Durham, Estibaliz Lopez Rodrigo, Omar Abdel-Wahab Nature Medicine volume 32（9）, pages 3491–3492  58 Author Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 作者勘误：多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie Gomez, Rachel A. DiCioccio, Eugene I. Hwang Nature Medicine volume 32（9）, page 3493 59 Author Correction: The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence 作者勘误：人工智能诊断准确性研究报告规范STARD-AI Viknesh Sounderajah, Ahmad Guni, Trishan Panch Nature Medicine volume 32（9）, page 3493 60 Author Correction: Integrated community-based HIV and sexual and reproductive health services for youth: a cluster-randomized trial 作者勘误：面向青少年的社区HIV与性生殖健康整合服务：整群随机试验 Rashida A. Ferrand, Ethel Dauya, Richard J. Hayes Nature Medicine volume 32（9）, page 3494 61 Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas 出版方勘误：CD19 CAR-T细胞在B细胞淋巴瘤体内可长达十年持续存在 Luca Paruzzo, Emeline R. Chong, Marco Ruella Nature Medicine volume 32（9）, page 3495 62 Editorial Expression of Concern: Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury 编辑部关切声明：遗传谱系示踪研究提示干细胞可修复损伤后成年哺乳动物心肌细胞 Patrick C. H. Hsieh, Vincent F. M. Segers, Richard T. Lee Nature Medicine volume 32（9）, page 3496 63 Editorial Expression of Concern: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis 编辑部关切声明：CDK4与Ras共表达可诱发人表皮恶性肿瘤 Mirella Lazarov, Yoshiaki Kubo, Paul A. Khavari Nature Medicine volume 32（9）, page 3497

LONDON & NEW YORK--(BUSINESS WIRE)-- $CMPS #Biotech --Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027. "We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass’ journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin," said Kabir Nath, Chief Executive Officer at Compass Pathways. "Reaching this critical inflection point requires our team to operate at the highest level, together. Kelley brings the right approach to people leadership to foster and build upon the culture of collaboration and support we’ve created at Compass, as well as to expand our capabilities in support of our expected transition from a clinical pioneer to a commercial stage company. Most importantly, Kelley understands that our people are central to realizing our vision of futures filled with possibilities for people living with serious mental health conditions." Ms. Boucher brings more than two decades of leadership experience building and scaling organizations across the biotechnology and healthcare sector, with a specific focus on innovative approaches in therapeutic areas where patients have been left with completely unmet medical needs. Prior to joining Compass, she served as Chief People Officer at Apellis Pharmaceuticals. Before Apellis, Ms. Boucher was Executive Vice President and Chief Human Resources Officer at Alnylam Pharmaceuticals, where she helped guide the company’s evolution from a research-focused organization into a global, commercial-stage biotechnology leader. Ms. Boucher has also held senior human resources leadership positions at Abiomed and Shire, supporting innovative organizations through periods of growth, transformation and increasing commercial complexity. She began her career at Syntonix Pharmaceuticals and Digitas. Ms. Boucher earned her bachelor’s degree from Cornell University. "It’s incredibly energizing and an honor to join a team working towards the potential to meaningfully change lives for people who have not found relief from existing psychiatric treatments," said Kelley Boucher, Chief People Officer at Compass Pathways. "I’m inspired by the purpose and passion that brings people to Compass, and the responsibility to deliver for patients that comes with it. I look forward to building upon the company’s strong culture, and fostering an environment where our people can bring their best, support and motivate each other, and work together to carry Compass forward into its next chapter.” About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing. Compass is headquartered in London, UK, with a U.S. office in New York. We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our business strategy and goals; our expectations regarding the timing of our rolling submission of a new drug application, or NDA, for COMP360 psilocybin treatment in TRD and the timing of the review by the Food and Drug Administration, or FDA, of such NDA, including potential acceleration due to the grant of rolling review and award of a National Priority Voucher for COMP360 psilocybin treatment in TRD; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all; and our expectations regarding potential commercial launch timelines and our commercial readiness. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the topline results; our need for substantial additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; that the rolling review process and/or the National Priority Voucher pilot program may not actually lead to a faster FDA review or approval process; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; the timing and substance of decisions by the Drug Enforcement Administration and states to reschedule COMP360 psilocybin treatment, if approved by FDA, which contains Schedule I controlled substances and must be rescheduled before commercializing COMP360 psilocybin in the U.S., may not be favorable; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q, and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at . Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof. Contacts Enquiries Media: Dana Sultan-Rothman, media@compasspathways.com Investors: Stephen Schultz, stephen.schultz@compasspathways.com , +1 401 290 7324